Vanesa López-Valverde

559 total citations
10 papers, 222 citations indexed

About

Vanesa López-Valverde is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Genetics. According to data from OpenAlex, Vanesa López-Valverde has authored 10 papers receiving a total of 222 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 3 papers in Genetics. Recurrent topics in Vanesa López-Valverde's work include Advanced Breast Cancer Therapies (6 papers), HER2/EGFR in Cancer Research (3 papers) and Breast Cancer Treatment Studies (3 papers). Vanesa López-Valverde is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), HER2/EGFR in Cancer Research (3 papers) and Breast Cancer Treatment Studies (3 papers). Vanesa López-Valverde collaborates with scholars based in Switzerland, Spain and United States. Vanesa López-Valverde's co-authors include Michael J. Mulvany, Ulf Simonsen, Edgaras Stankevıčıus, Luis Rivera, Alun D. Hughes, Sara A. Hurvitz, Aditya Bardia, Zhixin Xu, Jean Tessier and Gonzalo Spera and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Vanesa López-Valverde

10 papers receiving 218 citations

Peers

Countries citing papers authored by Vanesa López-Valverde

Since Specialization

Citations

This map shows the geographic impact of Vanesa López-Valverde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanesa López-Valverde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanesa López-Valverde more than expected).

Fields of papers citing papers by Vanesa López-Valverde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanesa López-Valverde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanesa López-Valverde. The network helps show where Vanesa López-Valverde may publish in the future.

Co-authorship network of co-authors of Vanesa López-Valverde

This figure shows the co-authorship network connecting the top 25 collaborators of Vanesa López-Valverde. A scholar is included among the top collaborators of Vanesa López-Valverde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanesa López-Valverde. Vanesa López-Valverde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE) 2023 ·Breast Cancer Research ·Sanne Lysbet de Haas, Dennis J. Slamon, Miguel Martín, Michael F. Press, Gail D. Lewis Phillips, Chiara Lambertini, Aleix Prat, Vanesa López-Valverde, Thomas Boulet, Sara A. Hurvitz	28
2	lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC). 2023 ·Journal of Clinical Oncology ·Charles E. Geyer, Aditya Bardia, Nadia Harbeck, Mothaffar F. Rimawi, Sara A. Hurvitz, Miguel Martín, Sherene Loi, Shigehira Saji, Kyung Hae Jung, Gustavo Werutsky, Daniil Stroyakovskiy, Vanesa López-Valverde, Michael Davis, Tanja Badovinac Črnjević, (unknown), Peter Schmid	5
3	Abstract OT2-03-02: lidERA Breast Cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy in patients with estrogen receptor+, HER2– early breast cancer 2023 ·Cancer Research ·Peter Schmid, Charles E. Geyer, Nadia Harbeck, Mothaffar F. Rimawi, Sara A. Hurvitz, (unknown), Sherene Loi, Shigehira Saji, Kyung Hae Jung, Gustavo Werutsky, (unknown), Vanesa López-Valverde, Michael J. Davis, Tanja Badovinac Črnjević, (unknown), Aditya Bardia	2
4	Abstract PD13-06: Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study 2022 ·Cancer Research ·Sara A. Hurvitz, Vanesa Quiroga, Yeon Hee Park, Aditya Bardia, Vanesa López-Valverde, Jutta Steinseifer, Tharu M. Fernando, Gonzalo Spera, (unknown), Peter A. Fasching	6
5	Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. 2022 ·Journal of Clinical Oncology ·Peter A. Fasching, Aditya Bardia, Vanesa Quiroga, Yeon Hee Park, (unknown), José Luis Alonso-Romero, Alexander Vasilyev, Hryhoriy Adamchuk, (unknown), Denise A. Yardley, Gonzalo Spera, (unknown), (unknown), Tanja Badovinac Črnjević, (unknown), Vanesa López-Valverde, Jutta Steinseifer, Tharu M. Fernando, Heather M. Moore, Sara A. Hurvitz	24
6	Abstract OT2-11-09: Lidera breast cancer: A phase III adjuvant study of giredestrant (GDC-9545) vs physician’s choice of endocrine therapy (ET) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+/HER2- EBC) 2022 ·Cancer Research ·Aditya Bardia, Peter Schmid, Nadia Harbeck, Mothaffar F. Rimawi, Sara A. Hurvitz, Sherene Loi, Shigehira Saji, Kyung Hae Jung, Gustavo Werutsky, (unknown), Vanesa López-Valverde, David Tesarowski, (unknown), Michael J. Davis, Tanja Badovinac Črnjević, (unknown), Charles E. Geyer	9
7	LBA14 Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) + palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study 2021 ·Annals of Oncology ·Sara A. Hurvitz, Y.H. Park, Aditya Bardia, Vanesa Quiroga, Vanesa López-Valverde, Jutta Steinseifer, Heather M. Moore, Gonzalo Spera, (unknown), Peter A. Fasching	13
8	Phase I Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the MEK Inhibitor RO4987655 (CH4987655) in Patients with Advanced Solid Tumors 2012 ·Clinical Cancer Research ·Suzanne Leijen, Mark R. Middleton, Patricia Tresca, Françoise Kraeber‐Bodéré, Véronique Dièras, M. E. Scheulen, Avinash Gupta, Vanesa López-Valverde, Zhixin Xu, Ruediger Rueger, Jean Tessier, Eliezer Shochat, (unknown), (unknown), Jan H.M. Schellens, Wilfried Eberhardt	55
9	Combination of Ca²⁺‐activated K⁺ channel blockers inhibits acetylcholine‐evoked nitric oxide release in rat superior mesenteric artery 2006 ·British Journal of Pharmacology ·Edgaras Stankevıčıus, Vanesa López-Valverde, Luis Rivera, Alun D. Hughes, Michael J. Mulvany, Ulf Simonsen	72
10	Glibenclamide Reveals Role for Endothelin in Hypoxia-Induced Vasoconstriction in Rat Intrapulmonary Arteries 2005 ·Journal of Cardiovascular Pharmacology ·Vanesa López-Valverde, Charlotte Uggerhøj Andersen, Britt Elmedal Laursen, Michael J. Mulvany, Ulf Simonsen	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact